Effects of α-difluoromethylornithine on local recurrence and pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice

Clinical and Experimental Metastasis

Volumn 20, Issue 4, 2003, Pages 321-325

  Manni, Andrea ^a,c   Washington, Sharlene ^a   Craig, Laura ^a   Cloud, Michael ^a   Griffith, James W ^a   Verderame, Michael F ^a   Texter, Lindsay J ^a   Mauger, David ^a   Demers, Laurence M ^a   Harms, John F ^a   Welch, Danny R ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Human breast cancer; Metastasis; Ornithine decarboxylase; Polyamines

Indexed keywords

EFLORNITHINE; GREEN FLUORESCENT PROTEIN; ORNITHINE DECARBOXYLASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOSYNTHESIS; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; GROWTH INHIBITION; HUMAN; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; EFLORNITHINE; ENZYME INHIBITORS; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT PROTEINS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; ORNITHINE DECARBOXYLASE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0038199842     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024055522067     Document Type: Article

References (12)

1. Glikman P, Vegh I, Pollina A et al. Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone in human breast cancer. Cancer 1987; 60: 2237-43.
2. Cañizares F, Salinas J, de las Heras M et al. Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: Correlation with clinicopathologic parameters. Clin Cancer Res 1999; 5: 2035-41.
3. Manni A, Manger D, Gimotty P et al. Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer. Clin Cancer Res 1996; 2: 1901-5.
4. Manni A, Washington S, Griffith JW et al. Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells. Clin Exp Metastasis 2002; 19: 95-105.
5. Manni A, Fischer S, Franks M et al. S-adenosylmethionine decarboxylase (SAMDC) overexpression reduces invasiveness and tumorigenicity in nude mice of MCF-7 breast cancer cells. Int J Oncol 2001; 19: 317-23.
6. Hortobagyi GN. Adjuvant systemic therapy for early breast cancer: Progress and controversies. Clin Cancer Res 2001; 7: 1839-42.
7. Manni A, Badger B, Martel J et al. Role of polyamines in the growth of hormone-responsive and -resistant human breast cancer cells in nude mice. Cancer Lett 1992; 66: 1-9.
8. Manni A, Badger B, Luk G et al. Role of polyamines in the growth of hormone-responsive experimental breast cancer in vivo. Breast Cancer Res Treat 1988; 11: 231-40.
9. Manni A, Astrow SH, Gammon S et al. Immunohistochemical detection of ornithine-decarboxylase in primary and metastatic human breast cancer specimens. Breast Cancer Res Treat 2001; 67: 147-56.
10. Early Breast Cancer Trialists' Collaborative Gropu. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998; 351: 1451-67.
11. Fisher B, Dignam J, Bryan J et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial. JNCI 2001; 93: 684-90.
12. Abrams JS. Tamoxifen: Five versus ten years - is the end in sight? JNCI 2001; 93: 662-4.